Leukotriene antagonism in asthma and rhinitis

Creticos, 1995, Allergic rhinitis, 1394 Watson, 1993, Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airways responsiveness, J Allergy Clin Immunol, 91, 97, 10.1016/0091-6749(93)90301-U Enarson, 1987, Asthma, asthma-like symptoms, chronic bronchitis and the degree of bronchial hyperresponsiveness in epidemiological surveys, Am Rev Respir Dis, 136, 613, 10.1164/ajrccm/136.3.613 Hogg, 1991, Evidence for inflammation in asthma, Am Rev Respir Dis, 143, s39, 10.1164/ajrccm/143.3_Pt_2.S39 Djukanovic, 1990, Mucosa inflammation in asthma, Am Rev Respir Dis, 142, 434, 10.1164/ajrccm/142.2.434 Jeffery, 1987, Ultrastructural analysis of bronchial-mucosa in asthma, J Pathol, 151A, 58 Howarth, 1995, Mucosal cytokine expression in allergic rhinitis, Int Arch Allergy Immunol, 107, 390, 10.1159/000237048 Djukvanovic, 1996, Pathology of rhinitis and bronchial asthma, Clin Exp Allergy, 91, s44, 10.1111/j.1365-2222.1996.tb00659.x Barnes, 1995, Drug therapy — inhaled glucocorticoids for asthma, N Engl J Med, 332, 868, 10.1056/NEJM199503303321307 1994, International report on the diagnosis and management of rhinitis, Allergy, 49, s1 Reiss, 1997, Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids, Thorax, 52, 45, 10.1136/thx.52.1.45 Kelleway, 1940, The liberation of a slow reacting smooth muscle stimulating substance of anaphylaxis, Quart J Exp Physiol, 30, 124 Morris, 1980, Structure of slow reacting substance of anaphylaxis from guinea pig lung, Nature, 285, 104, 10.1038/285104a0 Lewis, 1980, Slow reacting substance of anaphylaxis: identification of leukotriene C-1 and D from human and rat sources, 77, 3712 Samuelsson, 1980, Leukotrienes and slow reacting substance of anaphylaxis (SRS-A), Allergy, 35, 375, 10.1111/j.1398-9995.1980.tb01782.x Nasser, 1996, Lipid mediators — Leukotrienes, Prostanoids and platelet activating factor, 380 Dixon, 1990, Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis, Nature, 343, 282, 10.1038/343282a0 Kargman, 1993, Leukotriene synthesis in U937 cells expressing recombinant 5-lipoxygenase, J Lipid Mediators, 7, 31 Williams, 1984, Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators, J Immunol, 132, 3034, 10.4049/jimmunol.132.6.3034 Weller, 1983, Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4, 80, 7626 Feinmark, 1986, Endothelial cell leukotriene C4 synthesis results from intercellular transfer of leukotriene A4 synthesized by polymorphonuclear leukocytes, J Biol Chem, 261, 16 466, 10.1016/S0021-9258(18)66589-5 Coleman, 1995, Prostanoid and leukotriene receptors — a progress report from the IUPHAR Working Parties on Classification and Nomenclature, Adv Prostaglandin Thromboxane Leukotriene Res, 23, 283 Drazen, 1980, Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro, 77, 4354 Goldman, 1984, Selective transduction of human polymorphonuclear leukocyte functions by subsets of receptors for leukotriene B4, J Allergy Clin Immunol, 74, 373, 10.1016/0091-6749(84)90133-7 Dahlén, 1981, Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response, 78, 3887 McIntyre, 1986, Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils, 83, 2204 Laitinen, 1993, Leukotriene-E4 and granulocytic infiltration into asthmatic airways, Lancet, 341, 989, 10.1016/0140-6736(93)91073-U Dahlen, 1980, Leukotrienes are potent constrictors of human bronchi, Nature, 288, 484, 10.1038/288484a0 Adelroth, 1986, Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls, N Engl J Med, 315, 480, 10.1056/NEJM198608213150803 Davidson, 1987, Bronchoconstrictor effects of leukotriene-E4 in normal and asthmatic subjects, Am Rev Respir Dis, 135, 333 Barnes, 1984, Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects, Thorax, 39, 500, 10.1136/thx.39.7.500 O'Hickey, 1988, The relative responsiveness to inhaled leukotriene-E4, methacholine and histamine in normal and asthmatic subjects, Eur Resp J, 1, 913, 10.1183/09031936.93.01100913 Arm, 1990, Asthmatic airways have a disproportionate hyperresponsiveness to LTE4, as compared with normal airways, but not to LTC4, LTD4, methacholine and histamine, Am Rev Respir Dis, 142, 1112, 10.1164/ajrccm/142.5.1112 Kern, 1986, Characterization of the airway response to inhaled leukotriene D4 in normal subjects, Am Rev Respir Dis, 131, 1127 Smith, 1985, The effect of inhaled leukotriene D4 in humans, Am Rev Respir Dis, 131, 368 O'Hickey, 1991, Leuoktriene-C4, Leukotriene-D4, and leukotriene-E4 enhance histamine responsiveness in asthmatic airways, Am Rev Respir Dis, 144, 1053, 10.1164/ajrccm/144.5.1053 Christie, 1992, Effect of indomethacin on leukotriene E4-induced histamine hyperresponsiveness in asthmatic subjects, Am Rev Respir Dis, 146, 1506, 10.1164/ajrccm/146.6.1506 Smith, 1992, Urinary leukotriene-E4 in bronchial-asthma, Eur Respir J, 5, 693, 10.1183/09031936.93.05060693 Maltby, 1990, Leukotriene C4 elimination and metabolism in man, J Allergy Clin Immunol, 85, 3, 10.1016/0091-6749(90)90214-O Westcott, 1991, Urinary leukotriene E4 in patients with asthma, Am Rev Respir Dis, 143, 1322, 10.1164/ajrccm/143.6.1322 Christie, 1994, Increased urinary LTE(4) excretion following inhalation of LTC(4) and LTE(4) in asthmatic subjects, Eur Resp J, 7, 907, 10.1183/09031936.94.07050907 Wenzel, 1990, Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge, Am Rev Respir Dis, 142, 112, 10.1164/ajrccm/142.1.112 Wenzel, 1991, Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses, J Allergy Clin Immunol, 87, 540, 10.1016/0091-6749(91)90013-E Manning, 1990, Urinary leukotriene E4 levels during early and late asthmatic responses, J Allergy Clin Immunol, 86, 211, 10.1016/S0091-6749(05)80068-5 Kumlin, 1992, Urinary excretion of leukotriene-E4 and 11-dehydro-thromboxane-B2 in response to bronchial provocations with allergen, aspirin, leukotriene-D4, and histamine in asthmatics, Am Rev Respir Dis, 146, 96, 10.1164/ajrccm/146.1.96 Nasser, 1994, Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses, Thorax, 49, 743, 10.1136/thx.49.8.743 Pliss, 1990, Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma, Am Rev Respir Dis, 142, 73, 10.1164/ajrccm/142.1.73 Smith, 1991, Leukotriene-E4 levels after allergen and exercise challenge in bronchial asthma, Am Rev Respir Dis, 144, 1411, 10.1164/ajrccm/144.6.1411 Kikawa, 1992, Urinary leukotriene E4 after exercise challenge in children with asthma, J Allergy Clin Immunol, 89, 1111, 10.1016/0091-6749(92)90294-C Christie, 1991, Urinary leukotriene-E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects, Am Rev Respir Dis, 143, 1025, 10.1164/ajrccm/143.5_Pt_1.1025 Christie, 1992, Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects, Am Rev Respir Dis, 146, 1531, 10.1164/ajrccm/146.6.1531 Sladek, 1994, Eicosanoids in bronchoalveolar lavage fluid of aspirin-tolerant patients with asthma after aspirin challenge, Am J Respir Crit Care Med, 149, 940, 10.1164/ajrccm.149.4.8143059 Picado, 1992, Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients, Am Rev Respir Dis, 145, 65, 10.1164/ajrccm/145.1.65 Lam, 1988, Release of leukotrienes in patients with bronchial asthma, J Allergy Clin Immunol, 81, 711, 10.1016/0091-6749(88)91043-3 Wardlaw, 1989, Leukotrienes, LTC4 and LTB4 in brochoalveolar lavage in bronchial-asthma and other respiratory diseases, J Allergy Clin Immunol, 84, 19, 10.1016/0091-6749(89)90173-5 Drazen, 1992, Recovery of leukotriene-E4 from the urine of patients with airway obstruction, Am Rev Respir Dis, 146, 104, 10.1164/ajrccm/146.1.104 Naclerio, 1991, The role of leukotrienes in allergic rhinitis — a review, Am Rev Respir Dis, 143, S91, 10.1164/ajrccm/143.5_Pt_2.S91 Miadonna, 1987, Behaviour and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis, Am Rev Respir Dis, 136, 357, 10.1164/ajrccm/136.2.357 Creticos, 1984, Peptide leukotriene release after antigen challenge in patients sensitive to ragweed, N Eng J Med, 310, 1626, 10.1056/NEJM198406213102502 Georgitis, 1991, Nasal inflammatory mediator release in ragweed allergic rhinitis — correlation with cellular influx into nasal secretions, Int Arch Allergy Appl Immunol, 96, 231, 10.1159/000235500 Wilson, 1994, Mediator and cellular events in naturally ocurring seasonal allergic rhinitis, Clin Exp Allergy, 24, 997A Skoner, 1990, Nasal physiology and inflammatory mediators during natural pollen exposure, Ann Allergy, 65, 206 Volovitz, 1987, Leukotriene-C4 (LTC4) release in respiratory mucosa during natural exposure to ragweed in ragweed sensitive children, Ped Research, 21, A506 Knani, 1992, Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis, J Allergy Clin Immunol, 90, 880, 10.1016/0091-6749(92)90460-J Bentley, 1992, Immunohistology of the nasal mucosa in seasonal allergic rhinitis — increases in activated eosinophils and epithelial mast-cells, J Allergy Clin Immunol, 89, 877, 10.1016/0091-6749(92)90444-7 Durham, 1992, Cytokine mRNA expression of IL-2, IL-4, IL-5 and GM-CSF in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia, J Immunol, 148, 2390, 10.4049/jimmunol.148.8.2390 Naclerio, 1994, Basophils and Eosinophils in allergic rhinitis, J Allergy Clin Immunol, 94, 1303, 10.1016/0091-6749(94)90346-8 Bisgaard, 1986, Effect of leukotriene D4 on nasal mucosal blood-flow, nasal airway-resistance and nasal secretions in humans, Clin Allergy, 16, 289, 10.1111/j.1365-2222.1986.tb01960.x Okuda, 1988, The role of leukotriene-D4 in allergic rhinitis, Ann Allergy, 60, 537 Israel, 1993, The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma, Ann Intern Medic, 119, 1059, 10.7326/0003-4819-119-11-199312010-00001 Spector, 1994, Effects of 6 weeks therapy with oral doses of ICI 204 219, a leukotriene D4 receptor antagonist in subjects with bronchial asthma, Am J Respir Crit Care Med, 150, 618, 10.1164/ajrccm.150.3.8087328 Augstein, 1973, Selective inhibitor of slow reacting substance of anaphylaxis, Nature, 254, 215 Lee, 1981, Slow reacting substance if anaphylaxis antagonist FPL 55712 in chronic asthma, Lancet, ii, 304, 10.1016/S0140-6736(81)90547-X Jones, 1986, L-649 923, sodium (beta S∗, gamma R∗)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-gammahydroxy-beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist, Can J Physiol Pharmacol, 64, 1068, 10.1139/y86-183 Barnes, 1987, The effect of an oral leukotriene antagonist L-649 923 on histamine and leukotriene D4-induced bronchoconstriction in normal man, J Allergy Clin Immunol, 79, 816, 10.1016/0091-6749(87)90215-6 Phillips, 1988, Dose-related antagonism of leukotriene-D4-induced bronchoconstriction by po administration of Ly-171883 in nonasthmatic subjects, J Pharmacol Exp Therap, 246, 732 Wood-Baker, 1991, The effect of inhaled Ly-170680 on leukotriene-D4-induced bronchoconstriction in healthy volunteers, Drug Invest, 3, 239, 10.1007/BF03259572 Joos, 1991, The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics, Pulmon Pharmacol, 4, 37, 10.1016/0952-0600(91)90037-4 Krell, 1990, The preclinical pharmacology of ICI 204 219, Am Rev Respir Dis, 141, 978, 10.1164/ajrccm/141.4_Pt_1.978 Kips, 1991, MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human, Am Rev Respir Dis, 144, 617, 10.1164/ajrccm/144.3_Pt_1.617 DeLepeleire, 1997, Montelukast causes prolonged, potent leukotriene D-4-receptor antagonism in the airways of patients with asthma, Clin Pharmacol Therap, 61, 83, 10.1016/S0009-9236(97)90184-3 Fuller, 1989, Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects, J Allergy Clin mmunol, 83, 939, 10.1016/0091-6749(89)90109-7 Britton, 1987, The effect of an oral leukotriene D4 antagonist L-649 923 on the response to inhaled antigen in asthma, J Allergy Clin Immunol, 79, 811, 10.1016/0091-6749(87)90214-4 Taylor, 1991, Effect of cysteinyl-leukotriene receptor antagonist ICI 204 219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects, Lancet, 337, 690, 10.1016/0140-6736(91)90277-V O'Shaughnessy, 1993, Potent leukotriene D4 receptor antagonist ICI 204 219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction, Am Rev Respir Dis, 147, 1431, 10.1164/ajrccm/147.6_Pt_1.1431 Findlay, 1992, Effect of the oral leukotriene antagonist, ICI 204 219, on antigen-induced bronchoconstriction in subjects with asthma, J Allergy Clin Immunol, 89, 1040, 10.1016/0091-6749(92)90227-S Dahlen, 1994, The leukotriene-antagonist ICI-204 219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics, Eur Resp J, 7, 324, 10.1183/09031936.94.07020324 Rasmussen, 1992, Leukotriene-D(4) receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma, J Allergy Clin Immunol, 90, 193, 10.1016/0091-6749(92)90071-9 Christie, 1991, The potent and selective sulfidopeptide leukotriene antagonist, SK-and-F-104 353, inhibits aspirin-induced asthma, Am Rev Respir Dis, 144, 957, 10.1164/ajrccm/144.4.957 Kumlin, 1992, The leukotriene antagonist MK-0679 improves baseline pulmonary function and blocks aspirin-induced airways obstruction in aspirin-sensitive asthmatics, Am Rev Respir Dis, 145, A15 Israel, 1989, Effect of a leukotriene antagonist, LY 171883, on cold air-induced bronchoconstriction in asthmatics, Am Rev Respir Dis, 140, 1348, 10.1164/ajrccm/140.5.1348 Robuschi, 1992, Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F-104353) — a double-blind-study versus disodium-cromoglycate and placebo, Am Rev Respir Dis, 145, 1285, 10.1164/ajrccm/145.6.1285 Makker, 1993, The protective effect of inhaled leukotriene-D(4) receptor antagonist ICI-204 219 against exercise-induced asthma, Am Rev Respir Dis, 147, 1413, 10.1164/ajrccm/147.6_Pt_1.1413 Manning, 1990, Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 antagonist, N Engl J Med, 323, 1736, 10.1056/NEJM199012203232504 Bronsky, 1997, Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval, Clin Pharmacol Therap, 62, 556, 10.1016/S0009-9236(97)90051-5 Kemp, 1997, Montelukast, a leukotriene receptor antagonist, inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children, J Allergy Clin Immunol, 99, 1314 Reiss, 1997, Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist, Thorax, 52, 1030, 10.1136/thx.52.12.1030 Strek, 1997, Pranlukast (Ultair™) inhibits cold air-induced bronchoconstriction in patients with asthma, J Allergy Clin Immunol, 99, 1342 Ellis, 1994, Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi, Am J Respir Crit Care Med, 149, 118, 10.1164/ajrccm.149.1.8111568 Impens, 1993, Acute bronchodilation with an intravenously administered leukotriene- D(4) antagonist, MK-679, Am Rev Respir Dis, 147, 1442, 10.1164/ajrccm/147.6_Pt_1.1442 Hui, 1991, Lung-function improvement in asthma with a cysteinyl-leukotriene receptor antagonist, Lancet, 337, 1062, 10.1016/0140-6736(91)91709-4 Gaddy, 1992, Bronchodilation with a potent and selective leukotriene-D4 (LTD4) receptor antagonist (MK-571) in patients with asthma, Am Rev Respir Dis, 146, 358, 10.1164/ajrccm/146.2.358 Dahlen, 1993, Effect of the leukotriene receptor antagonist MK-0679 on base-line pulmonary-function in aspirin-sensitive asthmatic subjects, Thorax, 48, 1205, 10.1136/thx.48.12.1205 Smith, 1997, Intravenous pranlukast (Ultair™) inhibits LTD(4)-induced bronchoconstriction in patients with asthma, J Allergy Clin Immunol, 99, 1341 Cloud, 1989, A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma, Am Rev Respir Dis, 140, 1336, 10.1164/ajrccm/140.5.1336 Reiss, 1996, Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD(4)) receptor antagonist, in patients with chronic asthma, J Allergy Clin Immunol, 98, 528, 10.1016/S0091-6749(96)70086-6 Fujimura, 1993, Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma, Respir Med, 87, 133, 10.1016/0954-6111(93)90141-L Fish, 1997, Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study, Clin Therap, 19, 675, 10.1016/S0149-2918(97)80092-6 Suissa, 1997, Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma — a randomized, double-blind, placebo-controlled trial, Ann Intern Med, 126, 177, 10.7326/0003-4819-126-3-199702010-00001 Wechsler, 1998, Pulmonary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving receiving zafirlukast, J Am Med Assoc, 279, 455, 10.1001/jama.279.6.455 Wahedna, 1992, Effect of multiple doses of RG 12525, an oral leukotriene D4 antagonist, in chronic asthma, Am Rev Respir Dis, 145, A16 Tamaoki, 1997, Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid, Am J Respir Crit Care Med, 155, 1235, 10.1164/ajrccm.155.4.9105060 Oosaki, 1997, Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma, Int Arch Allergy Immunol, 114, 97, 10.1159/000237651 Barnes, 1997, Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicentre clinical study in asthma, Thorax, 52, 523, 10.1136/thx.52.6.523 Grossman, 1997, Results of the first US double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist, J Asthma, 34, 321, 10.3109/02770909709067222 Flowers, 1990, The effect of leukotriene antagonist on the early response to antigen, Otolaryngol Head Neck Surg, 102, 219, 10.1177/019459989010200303 Donnelly, 1995, The leukotriene D4 receptor antagonist, ICI 2 204,219, relieves symptoms of acute seasonals rhinitis, Am J Respir Crit Care Med, 151, 1734, 10.1164/ajrccm.151.6.7767514 Grossman, 1997, Pranlukast (Ultair™, SB 205312, ONO-1078), an oral leukotriene receptor antagonist, relieves symptoms in patients with seasonal allergic rhinitis (SAR), J Allergy Clin Immunol, 99, 1799 Evans, 1991, 5-lipoxygenase-activating protein is the target of a quinolone class of leukotriene biosynthesis inhibitors, Mole Pharmacol, 40, 22 Garland, 1991, Hydroxamic acids and hydroxureas as inhibitors of arachidonate 5-lipoxygenase, Drugs Future, 16, 547 Hui, 1991, Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients, Thorax, 46, 184, 10.1136/thx.46.3.184 Friedman, 1993, Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses, Am Rev Respir Dis, 147, 839, 10.1164/ajrccm/147.4.839 Diamant, 1995, The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in-vivo, J Allergy Clin Immunol, 95, 42, 10.1016/S0091-6749(95)70151-6 Israel, 1993, The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin, Am Rev Respir Dis, 148, 1447, 10.1164/ajrccm/148.6_Pt_1.1447 Nasser, 1994, Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma, Thorax, 49, 749, 10.1136/thx.49.8.749 Israel, 1990, The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air, N Engl J Med, 323, 1740, 10.1056/NEJM199012203232505 Meltzer, 1996, Inhibition of exercise-induced bronchospasm by zileuton — a 5-lipoxygenase inhibitor, Am J Respir Crit Care Med, 153, 931, 10.1164/ajrccm.153.3.8630575 Chapman, 1994, The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids, Am J Respir Crit Care Med, 149, A215 Liu, 1996, Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma — a 6-month randomized multicenter trial, J Allergy Clin Immunol, 98, 859, 10.1016/S0091-6749(96)80002-9 Knapp, 1990, Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-LO inhibitor, N Engl J Med, 323, 1740, 10.1056/NEJM199012203232506 Israel, 1996, Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma — a randomized controlled trial, J Am Med Assoc, 275, 931, 10.1001/jama.1996.03530360041036 DuBuske, 1997, Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms, Am J Managed Care, 3, 633 Schwartz, 1998, A randomised controlled trial comparing zileuton with theophylline in moderate asthma, Arch Intern Med, 158, 141, 10.1001/archinte.158.2.141 Howarth, 1995, The influence of 5-lipoxygenase inhibition in allergic rhinitis, Int Arch Allergy Immunol, 107, 423, 10.1159/000237065 Ancill, 1990, Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis, J Int Med Res, 18, 75, 10.1177/030006059001800202 Spaeth, 1996, Azelastine reduces histamine-induced swelling of nasal-mucosa, Orl-J- Oto-Rhino-Laryngol Related Specialities, 58, 157, 10.1159/000276817 Fischer, 1994, Direct evidence for a role of the mast-cell in the nasal response to aspirin in aspirin-sensitive asthma, J Allergy Clin Immunol, 94, 1046, 10.1016/0091-6749(94)90123-6 Owens, 1997, Focus on zileuton: the first FDA-approved agent of a new class of drugs for the management of asthma, Formulary, 32, 455 Spector, 1996, Management of asthma with zafirlukast-clinical experience and tolerability profile, Drugs, 52, 36, 10.2165/00003495-199600526-00007 Barnes, 1997, Worldwide clinical experience with the first marketed leukotriene receptor antagonist, Chest, 111, S52, 10.1378/chest.111.2_Supplement.52S Sorkness, 1997, The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma, Pharmacotherapy, 17, S50, 10.1002/j.1875-9114.1997.tb03701.x Kelloway, 1997, Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma, Ann Pharmacotherapy, 31, 1012, 10.1177/106002809703100912 1997 Marom, 1982, Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro, Am Rev Respir Dis, 126, 449 Camp, 1983, Response of human skin to intradermal injection of leukotrienes C4, D4 and B4, B J Pharmacol, 80, 497, 10.1111/j.1476-5381.1983.tb10721.x Soter, 1983, Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin, J Invest Dermatol, 80, 115, 10.1111/1523-1747.ep12531738 Michelassi, 1982, Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction, Science, 217, 841, 10.1126/science.6808665 Pfeffer, 1983, Systemic hemodynamic effects of leukotrienes C4 and D4 in the rat, Am J Physiol, 244, H628 Badr, 1984, Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rate, Circ Res, 54, 492, 10.1161/01.RES.54.5.492 Laitinen, 1993, Leukotriene E4 and granulocytic infiltration into asthmatic airways, Lancet, 341, 989, 10.1016/0140-6736(93)91073-U